JPWO2021175924A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021175924A5 JPWO2021175924A5 JP2022553036A JP2022553036A JPWO2021175924A5 JP WO2021175924 A5 JPWO2021175924 A5 JP WO2021175924A5 JP 2022553036 A JP2022553036 A JP 2022553036A JP 2022553036 A JP2022553036 A JP 2022553036A JP WO2021175924 A5 JPWO2021175924 A5 JP WO2021175924A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- kit according
- proteasome inhibitor
- pharmaceutical
- immunomodulatory imide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003949 imides Chemical class 0.000 claims description 18
- 230000002519 immonomodulatory effect Effects 0.000 claims description 18
- 229950001899 tasquinimod Drugs 0.000 claims description 18
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 claims description 18
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 17
- 239000003207 proteasome inhibitor Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229960001467 bortezomib Drugs 0.000 claims description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960003648 ixazomib Drugs 0.000 claims description 5
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 5
- 229960004942 lenalidomide Drugs 0.000 claims description 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 229960002204 daratumumab Drugs 0.000 claims description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- 108010064641 ONX 0912 Proteins 0.000 claims description 3
- 229960002438 carfilzomib Drugs 0.000 claims description 3
- 108010021331 carfilzomib Proteins 0.000 claims description 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 3
- 229950001466 delanzomib Drugs 0.000 claims description 3
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims description 3
- 229950002736 marizomib Drugs 0.000 claims description 3
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 3
- 229950005750 oprozomib Drugs 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 3
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 238000011284 combination treatment Methods 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984474P | 2020-03-03 | 2020-03-03 | |
| EP20160815 | 2020-03-03 | ||
| US62/984,474 | 2020-03-03 | ||
| EP20160815.5 | 2020-03-03 | ||
| US202163148522P | 2021-02-11 | 2021-02-11 | |
| US63/148,522 | 2021-02-11 | ||
| PCT/EP2021/055337 WO2021175924A1 (en) | 2020-03-03 | 2021-03-03 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519153A JP2023519153A (ja) | 2023-05-10 |
| JPWO2021175924A5 true JPWO2021175924A5 (pt) | 2024-02-07 |
Family
ID=74797955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553036A Pending JP2023519153A (ja) | 2020-03-03 | 2021-03-03 | 組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230085883A1 (pt) |
| EP (1) | EP4114368A1 (pt) |
| JP (1) | JP2023519153A (pt) |
| KR (1) | KR20220149579A (pt) |
| CN (1) | CN115209881A (pt) |
| AU (1) | AU2021229611A1 (pt) |
| BR (1) | BR112022016873A2 (pt) |
| CA (1) | CA3168070A1 (pt) |
| IL (1) | IL295780A (pt) |
| MX (1) | MX2022010327A (pt) |
| WO (1) | WO2021175924A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848826B (zh) * | 2022-07-06 | 2023-03-28 | 北京天宇恒泰科技有限公司 | 用于治疗胰腺癌的组合物及用途和评价系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| PT2590949E (pt) | 2010-07-09 | 2016-03-07 | Active Biotech Ab | Método para o fabrico de quinolina-3-carboxamidas |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| PL3041472T3 (pl) | 2014-09-23 | 2017-08-31 | Active Biotech Ab | Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego |
| CN106999540B (zh) * | 2014-10-30 | 2020-10-27 | 比格基因有限公司 | 组合疗法 |
| EA031643B1 (ru) | 2014-11-19 | 2019-01-31 | Эктив Байотек Аб | Применение тасквинимода для лечения острого лимфобластного лейкоза и острого миелоидного лейкоза |
| EP3067062A1 (en) * | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| KR102613430B1 (ko) * | 2016-10-19 | 2023-12-18 | 더 스크립스 리서치 인스티튜트 | 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도 |
-
2021
- 2021-03-03 IL IL295780A patent/IL295780A/en unknown
- 2021-03-03 CA CA3168070A patent/CA3168070A1/en active Pending
- 2021-03-03 AU AU2021229611A patent/AU2021229611A1/en active Pending
- 2021-03-03 MX MX2022010327A patent/MX2022010327A/es unknown
- 2021-03-03 CN CN202180018465.8A patent/CN115209881A/zh active Pending
- 2021-03-03 BR BR112022016873A patent/BR112022016873A2/pt unknown
- 2021-03-03 US US17/802,124 patent/US20230085883A1/en active Pending
- 2021-03-03 KR KR1020227034006A patent/KR20220149579A/ko unknown
- 2021-03-03 WO PCT/EP2021/055337 patent/WO2021175924A1/en unknown
- 2021-03-03 JP JP2022553036A patent/JP2023519153A/ja active Pending
- 2021-03-03 EP EP21708660.2A patent/EP4114368A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2246944C2 (ru) | Композиции, предназначенные для улучшения фертильности | |
| RU2336876C2 (ru) | Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества | |
| CA2180535C (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
| KR100338345B1 (ko) | 프로게스테론형제제및산화질소합성효소기질및(또는)산화질소공여물질의배합물을사용한자간전증및조산의치료 | |
| McDonald et al. | Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial | |
| KR20070010184A (ko) | 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물 | |
| IL168061A (en) | Compound 3 - (4 - amino - 1 - oxo - 1, 3 - dihydro - isoindole - 2 - il) - piperidine - 2, 6 - deion for the use of the drug for the treatment and regulation of myelodysplastic symptoms | |
| JP2006507271A5 (pt) | ||
| NZ569563A (en) | Methods for treating cutaneous lupus using aminoisoindoline compounds | |
| JP2007045839A5 (pt) | ||
| JP2009517411A5 (pt) | ||
| JP2008523102A (ja) | Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 | |
| SG172654A1 (en) | Extended cycle multiphasic oral contraceptive method | |
| JP2017525713A5 (pt) | ||
| JP2007511533A (ja) | 段階的エストロゲン避妊薬 | |
| Muzii et al. | Postoperative adhesion prevention with low-dose aspirin: effect through the selective inhibition of thromboxane production. | |
| US7569560B2 (en) | Extended cycle multiphasic oral contraceptive method | |
| JPWO2021175924A5 (pt) | ||
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| JPWO2019241442A5 (pt) | ||
| JP2007504223A5 (pt) | ||
| JPH0296525A (ja) | 医薬 | |
| JP2002544167A5 (pt) | ||
| JP2002544167A (ja) | 有機化合物 | |
| JP2005503391A5 (pt) |